Literature DB >> 30216585

The influence of voltage-gated sodium channels on human gastrointestinal nociception.

Matthew D Coates1, Kent E Vrana2, Victor Ruiz-Velasco3.   

Abstract

BACKGROUND: Abdominal pain is a frequent and persistent problem in the most common gastrointestinal disorders, including irritable bowel syndrome and inflammatory bowel disease. Pain adversely impacts quality of life, incurs significant healthcare expenditures, and remains a challenging issue to manage with few safe therapeutic options currently available. It is imperative that new methods are developed for identifying and treating this symptom. A variety of peripherally active neuroendocrine signaling elements have the capability to influence gastrointestinal pain perception. A large and growing body of evidence suggests that voltage-gated sodium channels (VGSCs) play a critical role in the development and modulation of nociceptive signaling associated with the gut. Several VGSC isoforms demonstrate significant promise as potential targets for improved diagnosis and treatment of gut-based disorders associated with hyper- and hyposensitivity to abdominal pain.
PURPOSE: In this article, we critically review key investigations that have evaluated the potential role that VGSCs play in visceral nociception and discuss recent advances related to this topic. Specifically, we discuss the following: (a) what is known about the structure and basic function of VGSCs, (b) the role that each VGSC plays in gut nociception, particularly as it relates to human physiology, and (c) potential diagnostic and therapeutic uses of VGSCs to manage disorders associated with chronic abdominal pain.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  abdominal pain; gastrointestinal disorders; visceral nociception; voltage-gated sodium channel

Year:  2018        PMID: 30216585     DOI: 10.1111/nmo.13460

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  7 in total

1.  Prevalence of primary painless chronic pancreatitis: A systematic review and meta-analysis.

Authors:  Furqan A Bhullar; Mahya Faghih; Venkata S Akshintala; Ahmed I Ahmed; Katie Lobner; Elham Afghani; Anna E Phillips; Phil A Hart; Mitchell L Ramsey; Benjamin L Bick; Louise Kuhlmann; Asbjørn M Drewes; Dhiraj Yadav; Søren S Olesen; Vikesh K Singh
Journal:  Pancreatology       Date:  2021-11-18       Impact factor: 3.996

2.  The Gain-of-Function R222S Variant in Scn11a Contributes to Visceral Hyperalgesia and Intestinal Dysmotility in Scn11a R222S/R222S Mice.

Authors:  Chenyu Zhao; Jishuo Jin; Haoye Hu; Xi Zhou; Xiaoliu Shi
Journal:  Front Neurol       Date:  2022-05-27       Impact factor: 4.086

3.  Homozygosity for the SCN10A Polymorphism rs6795970 Is Associated With Hypoalgesic Inflammatory Bowel Disease Phenotype.

Authors:  Eugene Gonzalez-Lopez; Yuka Imamura Kawasawa; Vonn Walter; Lijun Zhang; Walter A Koltun; Xuemei Huang; Kent E Vrana; Matthew D Coates
Journal:  Front Med (Lausanne)       Date:  2018-11-27

Review 4.  Silent Inflammatory Bowel Disease.

Authors:  Matthew D Coates; David G Binion
Journal:  Crohns Colitis 360       Date:  2021-09-22

5.  The Evidence for Effective Inhibition of INa Produced by Mirogabalin ((1R,5S,6S)-6-(aminomethyl)-3-ethyl-bicyclo [3.2.0] hept-3-ene-6-acetic acid), a Known Blocker of CaV Channels.

Authors:  Chao-Liang Wu; Chao-Wei Chuang; Hsin-Yen Cho; Tzu-Hsien Chuang; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

Review 6.  Marine Toxins and Nociception: Potential Therapeutic Use in the Treatment of Visceral Pain Associated with Gastrointestinal Disorders.

Authors:  Andreina Baj; Michela Bistoletti; Annalisa Bosi; Elisabetta Moro; Cristina Giaroni; Francesca Crema
Journal:  Toxins (Basel)       Date:  2019-07-31       Impact factor: 4.546

Review 7.  Tetrodotoxin: A New Strategy to Treat Visceral Pain?

Authors:  Ana Campos-Ríos; Lola Rueda-Ruzafa; Salvador Herrera-Pérez; Paula Rivas-Ramírez; José Antonio Lamas
Journal:  Toxins (Basel)       Date:  2021-07-16       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.